中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

36 records (took 0.018 seconds)

    DEGRON FUSION CONSTRUCTS AND METHODS FOR CONTROLLING PROTEIN PRODUCTION
    7.
    发明申请
    DEGRON FUSION CONSTRUCTS AND METHODS FOR CONTROLLING PROTEIN PRODUCTION 审中-公开
    降解熔融结构及控制蛋白质生产的方法

    公开(公告)号：WO2017004022A2

    公开(公告)日：2017-01-05

    申请号：PCT/US2016/039792

    申请日：2016-06-28

    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

    Inventor： LIN, Michael, Z. ,  CHUNG, Hokyung ,  JACOBS, Conor

    IPC: A61K39/12 ,  C12Q1/70

    CPC classification number: C12N9/506 ,  C07K14/02 ,  C07K2319/50 ,  C07K2319/95 ,  C12N9/48 ,  C12N15/86 ,  C12N2760/18443 ,  C12Q1/70 ,  C12Y304/21098 ,  G01N33/68

    Abstract: Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a czs-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired.

    Abstract translation: 公开了包含用于控制蛋白质生产的自切割degron的工程融合蛋白。 特别地，本发明人通过包含丙型肝炎病毒（HCV）蛋白酶位点的可切割接头，构建了包含连接于目的蛋白质的融合融合蛋白的融合蛋白。 通过czs编码的HCV蛋白酶可将degron从感兴趣的蛋白质中除去，使得可以以最小的结构修饰产生感兴趣的蛋白质。 临床可用的HCV蛋白酶抑制剂可用于阻断蛋白酶切割，使得在随后合成的蛋白质拷贝上加入抑制剂后保留脱落。 附着时的结构导致连接的蛋白质的快速降解。 当需要以最小的结构修饰来控制蛋白质生产时，这种融合蛋白质的融合将是特别有用的。

    DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OF
    8.
    发明申请
    DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OF 审中-公开
    生产定制设计的复制和不复制负链RNA病毒的DNA分子及其用途

    公开(公告)号：WO2016110869A4

    公开(公告)日：2016-10-27

    申请号：PCT/IN2016000004

    申请日：2016-01-04

    Applicant: JOSHI VISHWAS DATTATRAYA

    Inventor： JOSHI VISHWAS DATTATRAYA ,  MURTHY U M SREENIVASA ,  RANE SHAILENDRA DEVICHARAN ,  NADE MANASI SANJAY

    IPC: C12N15/45 ,  C12N7/01

    CPC classification number: C12N15/86 ,  C12N2760/18432 ,  C12N2760/18443 ,  C12N2770/24123 ,  C12N2770/24134 ,  C12N2840/20

    Abstract: This invention comprises: compositions comprising a derivative, plasmids, a reagent kit and methods of making these compositions a derivative, vaccine- and non-vacicine-compositions of above for causing death of cancer cells that form part of a tunoour and virus infected Denguue, Measles and other diseased cells; the derivative comprising replicating as well as non-replicating dervivaties of an attenuated negative stranded RNA virus belonging to family paramyxoviridae, including Measles Virus, comprising a single additional transcriptional unit carrying either only one or two or more non-viral genes, and the non-replicating derivatives being free from contaminating replicating Measles Virus (b) a Measles Virus packaging cell line for making above compositions, expressing the M, F and H proteins of MV stably. And (c) a reagent kit for producing the Measles Virus derivatives describved above.

    Abstract translation: 本发明包括：包含衍生物，质粒，试剂盒的组合物和制备这些组合物的上述衍生物，疫苗和非疫苗组合物的方法，所述组合物用于引起形成呼吸道和病毒感染Denguue的一部分的癌细胞死亡， 麻疹和其他病变细胞; 所述衍生物包含属于副粘病毒科（包括麻疹病毒）的减毒负链RNA病毒的复制以及非复制性衍生病毒，其包含仅携带一种或两种或更多种非病毒基因的单一额外转录单元， （b）用于制备上述组合物的麻疹病毒包装细胞系，稳定地表达MV的M，F和H蛋白。 （c）用于产生上述麻疹病毒衍生物的试剂盒。

    COMBINED MEASLES-HUMAN PAPILLOMA VACCINE
    10.
    发明申请
    COMBINED MEASLES-HUMAN PAPILLOMA VACCINE 审中-公开
    联合麻疹 - 人类乳头状病毒疫苗

    公开(公告)号：WO2010079505A2

    公开(公告)日：2010-07-15

    申请号：PCT/IN2009000302

    申请日：2009-05-26

    Applicant: CADILA HEALTHCARE LTD ,  MENDIRETTA SANJEEV K ,  GLUECK REINHARD ,  GIANNINO VIVIANA ,  CANTARELLA GIUSEPPINA ,  SCUDERI FRANCESCA ,  BILLETER MARTIN ,  FAZZIO AGATA

    Inventor： MENDIRETTA SANJEEV K ,  GLUECK REINHARD ,  GIANNINO VIVIANA ,  CANTARELLA GIUSEPPINA ,  SCUDERI FRANCESCA ,  BILLETER MARTIN ,  FAZZIO AGATA

    IPC: A61K39/00

    CPC classification number: A61K39/015 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5256 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2760/18434 ,  C12N2760/18443

    Abstract: The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost.

    Abstract translation: 本发明涉及针对麻疹和人乳头瘤病毒（HPV）的组合疫苗。 特别地，本发明涉及含有编码来自HPV的单个或多个抗原的异源核酸的重组麻疹病毒载体，优选地，主要的capside抗原L1，次要的capside抗原L2，早期的基因E6和HPV的早期基因E7癌蛋白 16型和任选18,6和11型。在第一个实施方案中，产生表达HPV抗原，优选L1和/或L2的预防性疫苗，使得它们在哺乳动物，优选人中诱导有效的长效免疫应答以 防止HPV和MV感染。 在另一个实施方案中，产生表达E6和E7蛋白以及任选L1和L2的治疗性疫苗，使得它们诱导强免疫应答将在包括HPV诱导的宫颈癌在内的早期或晚期阶段解决持续的HPV感染。 在一个优选实施方案中，组合疫苗易于大规模生产并且可以以低成本分发。

Patent Agency Ranking